Executive leadership changes at Weetabix

Sally Abbott, the present Managing Director of Weetabix, will step down to assume the role of strategic advisor from October 1 after nine years of helming the Weetabix brand portfolio.

She will be succeeded by Colm O’Dwyer, who is currently Commercial Director, and will continue working closely with him until her planned retirement on March 31, 2025, to ensure a smooth transition. The internal promotion is part of the company’s ongoing business succession planning.

In Sally’s tenure as MD, Weetabix weathered a variety of external economic challenges, as well as grew its portfolio with the acquisition Lacka Foods (UFit) in 2022 and Deeside Cereals in 2023.

Weetabix is currently evaluating candidates to backfill the Commercial Director role vacated by O’Dwyer’s promotion.

Abbott joined Weetabix in 2008 as Marketing Director, prior to the company’s ownership by US-based Post Holdings, which began in 2017.

O’Dwyer joined Weetabix in 2016 from Coca-Cola Enterprises in the U.K., eventually becoming General Manager of the Weetabix On-The-Go business. In 2018, he became Commercial Director, and added responsibility for Weetabix’s international business to his remit in 2022. O’Dwyer transformed Weetabix’s pricing and promotion strategy, evolved the company’s approach to customer relationships and reinvigorated Weetabix’s international strategy.

“Sally has been an exceptional leader, helping to successfully integrate Weetabix into Post and building on the success of this iconic company,” said Post’s President and Chief Executive Officer, Robert V. Vitale. “We wish Sally the best as she approaches her next chapter and congratulate Colm on his new role. Colm’s experience across innovation, brand management, revenue growth and customer relationships makes him exceptionally qualified to lead Weetabix.”